Aleve Sales Still Hit By NSAID Publicity; Roche Integration On Track – Bayer
This article was originally published in The Tan Sheet
Executive Summary
Sales of Aleve (naproxen sodium) continued to suffer during the second quarter due to NSAID class safety concerns, Bayer reported during an Aug. 10 earnings call from Leverkusen, Germany